---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-040585"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:44:48.394915+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx reports Q4 net loss $6.3M, cash $19.2M; Phase 2 Alport study ongoing, IND filed for ZKN-013

## Summary
- Net loss $6.3M ($2.92/share) vs $12.1M loss in Q4 2021; R&D and G&A expenses decreased YoY.
- Unrestricted cash $19.2M at Dec 31, 2022; amended Hercules loan repaid $7.5M; cash runway into Q3 2023.
- Three patients dosed in Phase 2 ELX-02 for Alport; initial proteinuria reduction observed; topline data H1 2023.
- IND filed for ZKN-013 for RDEB; preclinical read-through up to 18-fold increase in COL VII protein.

## SEC filing metadata
- accession: 0001104659-23-040585
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/0001104659-23-040585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/tm2311039d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-040585
- JSON: https://secwatch.observer/filing/0001104659-23-040585.json
- Plain text: https://secwatch.observer/filing/0001104659-23-040585.txt

## Key facts
- Earnings Releases
  Eloxx Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: net income net loss of $6.3 million, EPS $2.92 per share.
  - Period: the three months ended December 31, 2022
  - Net income: net loss of $6.3 million
  - EPS: $2.92 per share
  - Result: reported results
  source text: For the three months ended December 31, 2022, we incurred a net loss of $6.3 million, or $2.92 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/0001104659-23-040585-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.